Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ViroPedTher

Financiado

Oncolytic viruses for the treatment of pediatric brain tumors An integrated cli...

Oncolytic viruses for the treatment of pediatric brain tumors An integrated clinical and lab approach The overreaching goal of my lab is to improve the prognosis of patients with high-risk pediatric brain tumors. To this end, I propose to integrate clinical and lab-based research to develop tumor-targeted oncolytic adenoviruses wi... ver más

28/02/2025

UPNA

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 848

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-12

ERC-2018-COG: ERC Consolidator Grant

I+D

Cerrada hace 6 años

0% 100% 100%

2 Participantes

UPNA

2.00M€ | Lider

BSH ELECTRODOMESTICOS ESPAÑA

355.26K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCI2021-122084-2B TUMOR IMMUNE MICROENVIRONMENT (TIME) TARGETED THERAPY IN PED... 161K€ Cerrado

BIO2017-89754-C2-1-R ADENOVIRUS ONCOLITICOS PROTEGIDOS FRENTE AN ANTICUERPOS Y AR... 254K€ Cerrado

PRE2018-083292 ADENOVIRUS ONCOLITICOS PROTEGIDOS FRENTE AN ANTICUERPOS Y AR... 93K€ Cerrado

PID2020-119692RB-C21 ADENOVIRUS ONCOLITICOS QUE EXPRESAN PROTEINAS FORMADORAS DE... 266K€ Cerrado

EUIN2013-51221 PREPARACION DE PROPUESTA PARA HORIZONTE2020CUREMYELOMA 15K€ Cerrado

I-CREATE Fighting cancer with next generation oncolytic immunotherapy... 5M€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2019-02-12
Fecha Fin: 2025-02-28

Líder del proyecto

UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 848

Presupuesto del proyecto 2M€

Descripción del proyecto The overreaching goal of my lab is to improve the prognosis of patients with high-risk pediatric brain tumors. To this end, I propose to integrate clinical and lab-based research to develop tumor-targeted oncolytic adenoviruses with the capacity to elicit a therapeutic immune response in those tumors. Our research will use novel and relevant models to accomplish the experimental aims. We have previously worked with Delta-24-RGD (DNX-2401) a replication-competent adenovirus that has been translated to the clinical scenario. In 2017, the first clinical trial phase I with DNX-2401 for newly diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG; a lethal pediatric brain tumor) opened propelled by my team. Preliminary results from the first trials revealed that the intratumoral injection of the virus instigated an initial phase of oncolysis followed by a delayed inflammatory response that ultimately resulted in complete regression in a subset of the patients without associated toxicities. I hypothesized that enhancement of the immune component of the DNX-2401-based therapy will result in the complete regression of the vast majority of pediatric brain tumors. In our specific approach, we propose to understand the immune microenvironment of DIPGs and the response to viral therapy in the context of the trial. Moreover, that knowledge will leverage the design of Delta-24-based adenoviruses to recruit lymphocytes to the tumor with the competence of different type of ligands to activate the tumor infiltrating lymphocytes. I expect that this combinatorial innovative treatment will efficiently challenge the profound and inherent tumor immunosuppression and, in turn, will elicit a robust anti-tumor immune response resulting in the significant improvement of the prognosis and quality of life of patients with pediatric brain tumors. This project has the potential to produce a vertical advance in the field of pediatric oncology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores